Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-06-13
2010-10-19
Leavitt, Maria (Department: 1633)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S372000, C435S383000, C424S093700
Reexamination Certificate
active
07816140
ABSTRACT:
The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).
REFERENCES:
patent: 2004/0223953 (2004-11-01), Kung et al.
patent: WO 89/00198 (1989-01-01), None
patent: WO 2006/116678 (2006-11-01), None
Pierelli et al., Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.J Clin Oncol. Apr. 1999;17(4):1288.
Kucia et al., Bone marrow as a home of heterogenous populations of nonhematopoietic stem cells. Leukemia. Jul. 2005;19(7):1118-27.
Kucia et al., Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells.Biol Cell. Feb. 2005; 97(2):133-46.
Sasada et a., Expression of modified bFGF cDNAs in mammalian cells.Ann N Y Acad Sci. 1991;Abstract and pp. 149-160.
Watson et al., Recombinant DNA, Second Edition, 2nd ed. Distributed by W. H. Freeman and Company, 2001. pp. 153-155.
Stryer, Biochemistry, Third Edition, 1975, pp. 18-19.
Hall et al., Sca-1(+) hematopoietic cell-based gene therapy with a modified FGF-2 increased endosteal/trabecular bone formation in mice. Mol Ther. Oct. 2007;15(10):1881-9. Epub Jul. 17, 2007.
Chen et al., “Osteoblast precursor cells are found in CD34+cells from human bone marrow,”Stem Cells, 15(5):368-377, 1997.
D'Ippolito et al., “Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential,”J. Cell Science, 117:2971-2981, 2004.
Gysin et al., “Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in rats,”Gene Ther., 9(15):991-999, 2002.
Ishii et al., “Appropriate control of ex vivo gene therapy delivering basic fibroblast growth factor promotes successful and safe development of collateral vessels in rabbit model of hind limb ischemia,”J. Vasc. Surg.,39(3):629-638, 2004.
Kawaguchi et al., “Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2,”J. Clin. Endocrinol. Metab.,86(2):875-880, 2001.
Klamut et al., “Progress toward skeletal gene therapy,”Crit. Rev. Eukaryot. Gene Expr., 14(1-2):89-136, 2004.
Martin et al., “Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow,”Endocrinology, 138(10):4456-4462, 1997.
Mayahara et al., “In Vivo Stimulation of Endosteal bone Formation by Basic Fibroblast Growth Factor in Rats,”Growth Factors, 9:73-80, 1993.
Oakes and Lieberman, “Osteoinductive applications of regional gene therapy: ex vivo gene transfer,”Clin. Orthop. Relat. Res.,379S:S101-S112, 2000.
Olmsted-Davis et al., “Primitive adult hematopoietic stem cells can function as osteoblast precursors,”Proc. Natl. Acad. Sci. USA, 100(26):15877-15882, 2003.
Persons et al., “Retroviral-Mediated Transfer of the Green Fluorescent Protein Gene Into Murine Hematopoietic Cells Facilities Scoring and Selection of Transduced Progenitors in Vitro and Identification of Genetically Modified Cells in Vivo,”Blood, 90(5):1777-1786, 1997.
Seno et al., “Stabilizing Basic Fibroblast Growth Factor Using Protein Engineering,”Biochem. Biophys. Res. Comm., 151(2):701-708, 1988.
Trevisan et al., “Cycle Initiation and Colony Formation in Culture by Murine Marrow Cells With Long-Term Reconstituting Potential in Vivo,”Blood, 88(11):4149-4158, 1996.
Tuli et al., “Characterization of Multipotential Mesenchymal Progenitor Cells Derived from Human Trabecular Bone,”Stem Cells, 21:681-693, 2003.
Baylink David J.
Chen Shin-Tai
Hall Susan L.
Lau Kin-Hing William
Mohan Subburaman
Klarquist & Sparkman, LLP
Leavitt Maria
The United States of America as represented by the Department of
LandOfFree
Composition and methods for osteogenic gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and methods for osteogenic gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and methods for osteogenic gene therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169522